Drugs / HX009
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05731752 | May 2020 → Dec 2024 overdue | cancer | Hangzhou Hanx Biopharmaceuticals, Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04097769 | Jun 2019 → Mar 2021 | neoplasm | Waterstone Hanxbio Pty Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06708663 | Jan 2025 → Dec 2027 expected | biliary tract cancer, melanoma | Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05189093 | Dec 2021 → Jun 2025 | lymphoma | Hangzhou Hanx Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04886271 | May 2021 → Jan 2024 | neoplasm | Hangzhou Hanx Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HX009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05189093 ↗ |
| Action | Inhibit | “anti-CD47/PD-1” NCT05189093 ↗ |
| Modality | Protein / enzyme biologic | “anti-PD-1/CD47 infusion protein” NCT04097769 ↗ |
| Route | Intravenous | “via IV infusion” NCT04097769 ↗ |
| Target | CD47 | “anti-CD47/PD-1” NCT05189093 ↗ |